search
Back to results

Efficacy of Kerecis Omega 3 in Comparison to Clinical Standard Procedures

Primary Purpose

Leg Ulcer

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Kerecis Omega 3
Surgical debridement
Sponsored by
Insel Gruppe AG, University Hospital Bern
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leg Ulcer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Any chronic leg ulcer > 4 weeks duration with delayed wound healing (reduction of wound surface of less than 40-50% within 4 weeks under adequate local therapy) without underlying treatable medical conditions Ulcer area at between 5cm2 and 60cm2 Bacterial swab sampling prior to study Written study informed consent Exclusion Criteria: History of Fish allergy or proven Fish allergy Pregnant or breast-feeding women Intention to become pregnant during the course of the study Wound not suitable for dressing: inflammation, fibrin coatings Inability to understand the study consent

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Kerecis Omega 3

    Surgical debridement

    Arm Description

    Outcomes

    Primary Outcome Measures

    Change in ulcer surface area
    Change in ulcer surface area as assessed by standardized photography and digital imaging.

    Secondary Outcome Measures

    Change in patient quality of life
    Change in patient quality of life as assessed by the Wound-QoL questionnaire score, ranging from 0 to 4, with higher scores indicating a worse quality of life.
    Change in wound microbiota as assessed by alpha diversity of the microbial composition
    Change in wound microbiota utilizing 16S-sequencing from wound swabs as assessed by alpha diversity of the microbial composition trough Shannon index, with higher scores indicating a more diversity of the species
    Change in wound microbiota as assessed by beta diversity of the microbial composition
    Change in wound microbiota utilizing 16S-sequencing from wound swabs as assessed by beta diversity of the microbial composition trough Shannon index, with higher scores indicating a more diversity of the species.
    Change in ulcer surface area
    Change in ulcer surface area as assessed by standardized photography and digital imaging.

    Full Information

    First Posted
    March 15, 2023
    Last Updated
    September 6, 2023
    Sponsor
    Insel Gruppe AG, University Hospital Bern
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06036485
    Brief Title
    Efficacy of Kerecis Omega 3 in Comparison to Clinical Standard Procedures
    Official Title
    Efficacy of Kerecis Omega 3 Versus Standard of Care in Patients With Chronic Leg Ulcerations - a Randomized Trial With a New In-wound Split Design Approach
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2023
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Lack of funding to support the study
    Study Start Date
    May 1, 2023 (Actual)
    Primary Completion Date
    May 1, 2023 (Actual)
    Study Completion Date
    May 1, 2023 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Insel Gruppe AG, University Hospital Bern

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Chronic leg ulcerations are a great burden for patients and the medical system alike. Frequent outpatient consultations with associated treatment costs and travel costs for the patient as well as psychosocial burdens remain an unmet problem in chronic wound care. There is an increasing need for definitive treatment of especially chronic venous and multifactorial chronic leg ulceration where arterial intervention is not a treatment option. Minimal invasive surgical interventions that do not require skin grafting can be performed under local anesthesia in an outpatient setting even in multimorbid patients. Kerecis Omega3 Wound is intact decellularized fish skin. The fish skin sheets contain fat, protein, elastin, glycans and other natural skin elements and it can be an effective treatment option in chronic leg ulcerations and is licensed for this use as a medical product in Switzerland. However, limited data without inter-wound bias is available for the use of Kerecis Omega 3 in chronic leg ulcerations. In this study the investigators propose to investigate the efficacy of Kerecis Omega 3 according to objective wound surface measurements using standardized digital photographs in patients with chronic leg ulcerations. Efficacy will be evaluated against standard of care wound debridement.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Leg Ulcer

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Model Description
    1:1 in-wound split design with random allocation
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Kerecis Omega 3
    Arm Type
    Experimental
    Arm Title
    Surgical debridement
    Arm Type
    Active Comparator
    Intervention Type
    Device
    Intervention Name(s)
    Kerecis Omega 3
    Intervention Description
    Decellularized intact fish skin developed for the management of chronic wounds
    Intervention Type
    Procedure
    Intervention Name(s)
    Surgical debridement
    Intervention Description
    Superficial sharp surgical debridement technique
    Primary Outcome Measure Information:
    Title
    Change in ulcer surface area
    Description
    Change in ulcer surface area as assessed by standardized photography and digital imaging.
    Time Frame
    12 weeks
    Secondary Outcome Measure Information:
    Title
    Change in patient quality of life
    Description
    Change in patient quality of life as assessed by the Wound-QoL questionnaire score, ranging from 0 to 4, with higher scores indicating a worse quality of life.
    Time Frame
    2, 4, 6 and 12 weeks
    Title
    Change in wound microbiota as assessed by alpha diversity of the microbial composition
    Description
    Change in wound microbiota utilizing 16S-sequencing from wound swabs as assessed by alpha diversity of the microbial composition trough Shannon index, with higher scores indicating a more diversity of the species
    Time Frame
    2, 4, 6 and 12 weeks
    Title
    Change in wound microbiota as assessed by beta diversity of the microbial composition
    Description
    Change in wound microbiota utilizing 16S-sequencing from wound swabs as assessed by beta diversity of the microbial composition trough Shannon index, with higher scores indicating a more diversity of the species.
    Time Frame
    2, 4, 6 and 12 weeks
    Title
    Change in ulcer surface area
    Description
    Change in ulcer surface area as assessed by standardized photography and digital imaging.
    Time Frame
    2, 4, 6 and 12 weeks
    Other Pre-specified Outcome Measures:
    Title
    Incidence of adverse events
    Description
    Cumulative incidence of treatment-related adverse events
    Time Frame
    12 weeks

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Any chronic leg ulcer > 4 weeks duration with delayed wound healing (reduction of wound surface of less than 40-50% within 4 weeks under adequate local therapy) without underlying treatable medical conditions Ulcer area at between 5cm2 and 60cm2 Bacterial swab sampling prior to study Written study informed consent Exclusion Criteria: History of Fish allergy or proven Fish allergy Pregnant or breast-feeding women Intention to become pregnant during the course of the study Wound not suitable for dressing: inflammation, fibrin coatings Inability to understand the study consent
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Simon Bossart, MD
    Organizational Affiliation
    Department of dermatology, University Hospital Inselspital, Bern
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Efficacy of Kerecis Omega 3 in Comparison to Clinical Standard Procedures

    We'll reach out to this number within 24 hrs